We categorized the solid tumors into ICT “responsive” (including melanoma, lung, renal, head and neck, and esophageal cancers that have PD-1/PD-L1 therapy already FDA-approved) and ICT “refractory” (including breast, pancreatic, and prostate cancer, and glioblastoma that have no FDA-approved ICT) cohorts, and performed comparative analysis between the 9p21-WT and 9p21-loss tumors within each cohort. The gene discussed is CD274; the disease is esophageal cancer.